Top Health-care stocks:
Health-care shares were mixed in pre-market trade Monday.
In health-care stocks news, ARIAD Pharmaceuticals ( ARIA ) said a long-term follow up from a phase 2 trial with heavily pretreated leukemia patients shows its iclusig drug ponatinib continues to demonstrate anti-leukemic activity.
The study was in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Shares in the company were trading 0.41% higher at $7.40 during Monday's pre-market trading session. Over the past 52 weeks, the company has traded between $3.80 and $9.83.
Agios Pharmaceuticals ( AGIO ) shares also edged up in Monday's pre-market session after the biopharmaceutical company said larger biopharmaceutical company Celgene ( CELG ) has elected to extend the period of its exclusivity for an additional year to April 2016 under their global strategic collaboration agreement.
Shares in the company were trading 6.11% higher at $112.30 during Monday's pre-market trading session. Over the past 52 weeks, the company has traded between $17.65 and $111.60.
Meanwhile Advaxis ( ADXS ), a biotechnology company, said the U.S. Food and Drug Administration has cleared its Investigational New Drug application to conduct a Phase 1/2 clinical study to evaluate the combination of ADXS-PSA with KEYTRUDA, marketed by Merck ( MRK ), in patients with previously treated, metastatic castration-resistant prostate cancer.
Shares in the company were trading 6.36% higher at $3.68 during Monday's pre-market trading session. Over the past 52 weeks, the company has traded between $2.46 and $5.99.
And Kindred Healthcare (KND), a health-care services company, unveiled Monday the proposal of an offering of $1.35 billion of senior unsecured notes.
The company said that the terms of the notes, including interest rate, principal amount and maturity, would be determined at the time of pricing. The notes are expected initially to be issued by Kindred's subsidiary, Kindred Escrow Corp. II.
Shares in the company were unchanged during Monday's pre-market trading session at $19.09. Over the past 52 weeks, the company has traded between $17.26 and $26.81.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.